Neoadjuvant @entity136 , @entity1205 , and XXXX followed by @entity136 and @entity416 @entity1161 and surgery in locally advanced, unresectable @entity788 .

@entity1 @entity788 @entity137 @entity416 @entity1161 @entity5 @entity1205 @entity136
BACKGROUND: This prospective study was undertaken to assess @entity137 , resectability, and survival in @entity788 @entity1 presenting with locally advanced, unresectable disease treated with neoadjuvant @entity136 , @entity1205 , and @entity416 (GTX) and @entity136 and @entity416 (GX)/radiation therapy ( @entity1161 ). METHODS: All @entity1 presenting to the Pancreas Center were evaluated for eligibility. Forty-five @entity1 (mean age, 64 years; range, 44-83 years)-34 @entity1 deemed unresectable because of arterial involvement and 11 @entity1 deemed unresectable because of extensive venous involvement-were treated with 6 cycles of GTX. Those with arterial involvement were treated with GX/ @entity1161 after chemotherapy. RESULTS: The GTX and GX/ @entity1161 treatments were tolerated with the expected drug-related @entity137 . There were no bowel perforations, cases of @entity788 , or delayed strictures. Among those with arterial involvement, 29 underwent subsequent resection, with 20 (69%) achieving R0 resections. All 11 @entity1 with venous-only involvement underwent resection, with 8 achieving R0 resections and 3 achieving complete pathologic responses. For the arterial arm, the 1-year survival rate was 71% (24 of 34 @entity1 ), and the median survival was 29 months (95% confidence interval, 21-38 months). Thirteen @entity1 (38%) have not relapsed (range, 5-49+ months). For the venous arm, the median survival has not been reached at more than 42 months. Six @entity1 (55%) in the venous arm did not experience recurrence (range, 6.2-42+ months). CONCLUSIONS: GTX plus GX/ @entity1161 is an effective neoadjuvant regimen that can be safely administered to @entity1 up to at least the age of 83 years. It is associated with a high response rate, a high rate of R0 resections, and prolonged overall survival. @entity5 2014.    2014 American @entity5 Society.
